Fig. 1: The percentage of CD4+ T cells correlated with clinical prognosis and function of CIK cells.
From: CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
A Kaplan–Meier estimates of progression-free survival in the three (high, intermediate, and low) groups. B Kaplan–Meier estimates of overall survival in the three (high, intermediate, and low) groups. C Flow cytometric quality assessment of CIK cells after 14 days of ex vivo expansion before adoptive transfer to tumor-burdened NSG mice. D–F Subcutaneous growth of tumor cells (A549) in each group of mice (n = 4) treated with CD4+ T, CD4-CIK, and CIK cells. G Bioluminescent imaging of NSG mice from three groups treated with T-cell tracer. H Flow cytometric analysis of IFN-γ, GzmB, PD-1, and Tim-3 expression in CD3+CD8+ T cells. Error bars indicate SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (Kaplan–Meier, one-way ANOVA or Student's t test).
